Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Buffalo Local Index
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Silexion Therapeutics Corp - Ordinary Shares
(NQ:
SLXN
)
0.3690
+0.0194 (+5.55%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Oct 18, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
1,284,245
Open
0.3510
Bid (Size)
0.3465 (10)
Ask (Size)
0.3640 (14)
Prev. Close
0.3496
Today's Range
0.3462 - 0.4100
52wk Range
0.2720 - 4.650
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Silexion Therapeutics to Present at 2024 Maxim Healthcare Virtual Summit
October 09, 2024
Silexion Therapeutics to Present at 2024 Maxim Healthcare Virtual Summit
Via
News Direct
12 Health Care Stocks Moving In Friday's After-Market Session
October 04, 2024
Via
Benzinga
Performance
YTD
-81.08%
-81.08%
1 Month
-56.73%
-56.73%
3 Month
-81.08%
-81.08%
6 Month
-81.08%
-81.08%
1 Year
-81.08%
-81.08%
More News
Read More
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
October 02, 2024
Via
Benzinga
Silexion Investigational Pancreatic Cancer Treatment Shows Promise In Animal Studies
October 01, 2024
Via
Benzinga
Market Alert: Silexion Therapeutics (NASDAQ: SLXN) Sees Record Volumes Following Breakthrough Preclinical Data for SIL-204
October 01, 2024
Via
News Direct
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
October 01, 2024
Via
Benzinga
Silexion Therapeutics Unveils Promising Preclinical Data for SIL-204 Just Days After New LODER Data: Advancing the Fight Against Pancreatic Cancer
October 01, 2024
Via
AB Newswire
Silexion Therapeutics Reports Breakthroughs From SIL-204 Preclinical Studies
October 01, 2024
From
Silexion Therapeutics Corp.
Via
Business Wire
Silexion Therapeutics Stock Trades Higher, Trial Data For Pancreatic Cancer Patients Shows Promise
September 24, 2024
Via
Benzinga
Silexion Therapeutics Reports Promising Phase 2 Data for Non-Resectable Pancreatic Cancer Treatment
September 24, 2024
Via
AB Newswire
Silexion Therapeutics Announces Significant New Data from Phase 2 Trial of LODER™ in Non-Resectable Pancreatic Cancer
September 24, 2024
From
Silexion Therapeutics
Via
Business Wire
Industry Update: 3 Exciting Precision Oncology Players to Watch Following Summit’s Meteoric Rise: Silexion, Nuvectis, Scorpian
September 19, 2024
Via
AB Newswire
Industry Update: 3 Exciting Precision Oncology Players to Watch Following Summit’s Meteoric Rise: Silexion, Nuvectis, Scorpian
September 19, 2024
Via
News Direct
Why Dave & Buster's Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket
September 11, 2024
Via
Benzinga
Why Oracle Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket
September 10, 2024
Via
Benzinga
PESG Releases Report on Silexion Therapeutics: Pioneering RNAi Technology in the Fight Against KRAS-Driven Cancers
September 09, 2024
From
PESG Research
Via
Business Wire
Why Recursion Pharmaceuticals Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
September 03, 2024
Via
Benzinga
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.